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Abstract
Uncontrolled extracellular matrix (ECM) production by fibroblasts
in response to injury contributes to fibrotic diseases, including idio-
pathic pulmonary fibrosis (IPF). Reactive oxygen species (ROS)
generation is involved in the pathogenesis of IPF. Transforming
growth factor-b1 (TGF-b1) stimulates the production of NADPH
oxidase 4 (NOX4)-dependent ROS, promoting lung fibrosis (LF).
Dysregulation of microRNAs (miRNAs) has been shown to contri-
bute to LF. To identify miRNAs involved in redox regulation relevant
for IPF, we performed arrays in human lung fibroblasts exposed to
ROS. miR-9-5p was selected as the best candidate and we demon-
strate its inhibitory effect on TGF-b receptor type II (TGFBR2) and
NOX4 expression. Increased expression of miR-9-5p abrogates TGF-b1-
dependent myofibroblast phenotypic transformation. In the mouse
model of bleomycin-induced LF, miR-9-5p dramatically reduces
fibrogenesis and inhibition of miR-9-5p and prevents its anti-
fibrotic effect both in vitro and in vivo. In lung specimens from
patients with IPF, high levels of miR-9-5p are found. In omentum-
derived mesothelial cells (MCs) from patients subjected to peri-
toneal dialysis (PD), miR-9-5p also inhibits mesothelial to
myofibroblast transformation. We propose that TGF-b1 induces
miR-9-5p expression as a self-limiting homeostatic response.
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Introduction
The problem of organ fibrosis constitutes a major biomedical chal-
lenge. Fibrosis can be defined as an excessive accumulation of ECM
components leading to the irreversible replacement of cellular
compartments by ECM, ultimately leading to stiffness, scarring and
devitalized tissue [1]. While the past 25 years have witnessed a very
significant increment in our understanding of fibrogenesis from the
molecular standpoint, it is evident that very little progress has been
made toward the possibility of preventing, deferring, or curing
organ fibrosis. The fact that major organs such as the liver, heart,
kidney, or lung can be affected by fibrosis, in many cases with lethal
outcomes, adds an important and social burden to these clinical
conditions. Fibrosis of these organs underlies the development of
diseases with significant prevalence and scarce therapeutic margin
including liver cirrhosis, myocardial sclerosis, renal diabetic disease,
or IPF [2]. IPF is a chronic progressive and lethal fibrotic lung
disease of unknown etiology that is currently untreatable. The
majority of IPF patients die from respiratory failure within 2–5 years
of diagnosis [3,4]. The annual incidence of IPF appears to be rising,
the disease is more common in men and the prevalence rises signifi-
cantly with age [5,6].
IPF is one of the conditions where the established interaction
between TGF-b and disturbance of redox homeostasis is sustained
by a well-defined molecular mechanism [7]. TGF-b enhances the
expression of NOX4 in numerous cell types, leading to increased
oxidative stress, which in itself is capable of amplifying the powerful
fibrogenic program induced by TGF-b [8–10], thus leading to a
vicious cycle and self-perpetuating fibrotic response [11].
An important pathological scenario where the appearance of
fibrosis has a devastating effect is the peritoneum of patients
subjected to continuous PD. Peritoneal fibrosis (PF) leads to perito-
neal membrane failure and ultrafiltration dysfunction [12–14]. It has
been shown that peritoneal mesothelial cells (PMCs) play a crucial
role in the development and progression of PF through the
acquisition of a myofibroblast-like phenotype by mesothelial-to-
mesenchymal transition (MMT) [15,16].
miRNAs are short single-stranded RNAs that regulate post-
trancriptional mRNA expression by binding to complementary
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mRNA sequences, resulting in translational repression and gene
silencing [17,18]. These non-coding RNAs play critical roles in vari-
ous physiological processes such as tissue development and dif-
ferentiation, cellular proliferation and tissue repair [19,20]. Since
their discovery in humans [21], merely 15 years ago, a huge explo-
sion of knowledge has given rise to the hope that miRNAs may
represent therapeutic alternatives for many untreatable diseases
[22–25]. In this regard, the field of organ fibrosis has been the object
of intense investigation. miRNAs have been reported to form part of
the fibrogenic loop in different organs [26]. As one archetypical and
therapeutically challenging condition, IPF is a clinical entity where
increasing focus has been recently placed, leading to the description
of miR-21 as a mechanistic culprit in the activation of fibrogenesis
[27–29]. Several miRNAs have been reported to respond to pertur-
bations in the redox state [30] or to fibrogenic stimuli [26].
However, we are not aware of the existence of miRNAs combining
the double feature of being regulated by both oxidative stress and
pro-fibrotic cues involved in LF. In the present study, we sought to
identify potential members of this subset that could in addition
serve as new targets to be potentially exploited as therapeutic
avenues for IPF and other interstitial lung diseases.
Here, we report the identification of miR-9-5p, a miRNA previ-
ously unrelated to the phenomenon of fibrosis, targeting two key
mRNAs involved in fibrogenesis: TGFBR2 and NOX4. In addition,
we demonstrate that miR-9-5p operates in an anti-fibrogenic mode
in cellulo and in the bleomycin-induced animal model of LF by nega-
tively regulating the TGF-b signaling pathway. Moreover, we also
show that lungs from patients with IPF and PMCs derived from
patients subjected to PD both presented increased levels of miR-9-5p,
thus supporting its role in human organ fibrosis.
Results
Hydrogen peroxide modulates miRNA expression in human
lung fibroblasts
In order to determine the effect of oxidative stress on miRNA
expression, human fetal lung fibroblasts (HFL-1) were treated with
100 lM hydrogen peroxide (H2O2) for 8 h. RNA was isolated and
the miRNA expression profile was analyzed by Taqman arrays. Heat
map revealed clearly distinct expression patterns in some miRNAs
when comparing H2O2-treated with untreated control samples
(Fig 1A). A higher magnification view of the zone showing the more
differentially expressed miRNAs is depicted on the right. The
volcano plot analysis spotted a group of seven differentially expressed
miRNAs, five up- and two down-regulated miRNAs, in treated
samples compared to untreated ones (Fig 1B and Table EV1). The
quantitatively important change observed in miR-9-5p and the
absence of information on this miRNA in the context of organ
fibrosis encouraged us to focus on miR-9-5p as a potential candidate
susceptible of regulating redox-mediated fibrogenesis. Quantitative
reverse transcription–polymerase chain reaction (qRT–PCR) was
performed to confirm the change of miR-9-5p expression following
treatment with H2O2 that had been identified by miRNA expression
profiling (Fig 1C, white bars). Pre-incubation of HFL-1 cells with
PEG-catalase, a specific H2O2 scavenger, significantly abrogated
H2O2-mediated increase in both ROS production (Fig EV1A) and
miR-9-5p expression (Fig 1C, black bars), indicating that miR-9-5p
is up-regulated in oxidative stress conditions. TGF-b1, one of the
master regulators of fibrogenesis [31–33], also induced miR-9-5p
expression in HFL-1 cells more than 10-fold after 24-h treatment
(Fig 1D), supporting a potential role for miR-9-5p in TGF-b signaling-
related events. To evaluate the temporary course of miR-9-5p
induction by TGF-b1, the primary transcripts of miR-9 (pri-miR-9)
were analyzed by qRT–PCR after TGF-b1 stimulation. TGF-b1
induced the expression of both pri-miR-9-1 and pri-miR-9-3
(Fig EV1B), suggesting a possible regulation at the level of miRNA
transcription. TGF-b1 increased ROS production in different cell
types, including human lung fibroblasts (Fig EV1C). These TGF-b1-
induced ROS were found to be required for TGF-b1-induced
myofibroblast differentiation, ECM production, contractility and
more importantly in the establishment and progression of human LF
[8,10]. In order to analyze if the induction of miR-9-5p expression by
TGF-b1 was dependent on the TGF-b1-produced ROS, lung fibro-
blasts were pre-incubated with PEG-catalase before TGF-b1 treat-
ment. Catalase significantly decreased both ROS levels and miR-9-5p
expression induced by TGF-b1 (Figs 1E and EV1D), suggesting that
the TGF-b1-induced miR-9-5p expression was at least partially medi-
ated by ROS. In silico analysis of specific target genes for miR-9-5p
using three independent prediction tools (Targetscan, miRWalk and
miRanda) determined 940 common target genes (Appendix Fig S1A)
that are listed in Table EV2. Analysis using the DAVID database
revealed a number of pathways highly enriched in miR-9-5p target
genes. One of them was the “TGF-b signaling pathway” (P =
4.1 × 102) (Appendix Fig S1B), which is the major pathological
signaling pathway related to LF [2,34]. By intersecting the miR-9-5p
predicted targets with the genes involved in the TGF-b signaling
pathway (Table EV3), 16 genes were identified (Fig 1F and
Table EV4). Noticeably, two of them, NOX4 and TGFBR2, had
already been implicated in the pathogenesis of LF [8,10,35]. Hence,
we focused our analysis on these two genes.
TGFBR2 and NOX4 expression are regulated by miR-9-5p
The TargetScan prediction software identified 2 and 3 putative bind-
ing sites (BSs) for miR-9-5p in the 30 untranslated regions (30 UTRs)
of the TGFBR2 and NOX4 mRNA, respectively (Appendix Fig S2A
and B). This prediction was functionally validated by over-expressing
miR-9-5p in pulmonary fibroblasts (Appendix Fig S3), which
resulted in a decrease of TGFBR2 mRNA and protein levels (Fig 2A
and B) and also reduced the mRNA and protein expression of NOX4
after induction by TGF-b1 (Fig 2E and F). To determine whether
miR-9-5p directly regulates TGFBR2 and NOX4 expression by bind-
ing to their 30 UTR, putative WT and mutated 30 UTR were cloned
into the luciferase reporter vector pSiCheck-2 [36] (Fig 2C and G).
Transfection with pre-miR-5p significantly decreased the luciferase
activity of the reporter vector containing both WT 30 UTRs while this
reduction was abrogated in the presence of miRNA inhibitor-9
(Fig 2D and H). The decrease in the luciferase activity was comple-
tely abolished after point mutations (PM) in both miR-9-5p BSs in
the 30 UTR of TGFBR2 (Fig 2D). The reduction was observed neither
in the presence of PM1 + PM2 nor in the presence of
PM1 + PM2 + PM3 NOX4 30 UTR constructs (Fig 2H). These obser-
vations indicated that BS2 and both BS1 and BS2 were critical for
the regulation of TGFBR2 and NOX4 30 UTRs, respectively. These
ª 2015 The Authors EMBO reports Vol 16 | No 10 | 2015
Marta Fierro-Fernández et al miR-9-5p prevents organ fibrogenesis EMBO reports
1359
Published online: August 27, 2015 
Figure 1. miRNA expression data in human lung fibroblasts following stimulation with H2O2 or TGF-b1.
A Heat map showing relative miRNA expression between untreated (control) and H2O2-treated HFL-1 cells. The scale bar at the bottom left ranges from green to red
(low to high expression) and numbers represent DCt values. A blow-up of differentially expressed miRNAs is depicted on the right side. Data are representative of
results from two experiments performed independently.
B Volcano plot analysis of H2O2-modulated miRNAs. Log10 relative quantification (RQ) and negative () log10 adjusted (adj.) P-values are plotted on the x- and y-axis,
respectively. Each miRNA is represented by a colored dot, gray are down-regulated, purple are up-regulated and black are non-regulated (adj. P-value ≥ 0.05)
miRNAs.
C–E qRT–PCR analysis of miR-9-5p expression in HFL-1 cells pre-incubated for 2 h either with polyethyleneglycol (PEG) or with 100 units/ml PEG-catalase and treated
with 100 lM H2O2 for the indicated times (n = 3) (C), in cells treated with 5 ng/ml TGF-b1 for the indicated times (n = 3–8) (D) and in HFL-1 cells pre-incubated as
described in (C) and treated with 5 ng/ml TGF-b1 for 24 h (n = 4) (E). Bar graphs show mean  SEM; two-tailed Mann–Whitney U-test (C, E) and Kruskal-Wallis
non-parametric ANOVA (D); *P < 0.05, **P ˂ 0.01 compared to control cells, #P < 0.05 compared to the same time point of control cells and @P < 0.05 compared
to PEG-catalase-treated cells at time 0.
F Venn diagram showing the intersection of miR-9-5p targets and TGF-b-related genes.
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data are consistent with a direct regulation of TGFBR2 and NOX4 by
miR-9-5p.
miR-9-5p regulates TGF-b pro-fibrogenic signaling in human
lung fibroblasts
Pulmonary fibroblasts are the key effectors in the development of
LF [2,37]. TGF-b induces the transformation of fibroblasts into
myofibroblasts [38,39]. Myofibroblasts are one of the major sources
of ECM proteins, especially collagen type I alpha 1 (Col1a1) and
fibronectin (FN), and are commonly characterized by the presence
of a-smooth muscle actin (a-SMA) [37]. Uncontrolled activation,
proliferation, differentiation and survival of ECM-producing
myofibroblasts can perpetuate the pulmonary fibrotic response
[7,39]. To determine if miR-9-5p was involved in the pro-fibrogenic
transformation of pulmonary fibroblasts by TGF-b1, HFL-1 cells
were transfected with pre-miR-9-5p and treated with TGF-b1 for
different times. Increasing miR-9-5p levels significantly decreased the
TGF-b1-induced transcription of a-SMA, Col1a1 and FN (Fig 3A).
Similarly, over-expression of miR-9-5p strongly reduced a-SMA and
FN protein abundance (Fig 3B–E). Conversely, the knock-down of
miR-9-5p induced an increase in the TGF-b1-dependent transcription
of Col1a1 and FN (Fig EV2A) and in the a-SMA and FN protein
levels (Fig EV2B–E). To verify if TGFBR2 and NOX4 were the
relevant targets in this context, HFL-1 cells were transfected with
plasmids expressing TGFBR2 and NOX4 in order to “rescue” the
inhibitory effect potentially exerted by miR-9-5p on the correspond-
ing endogenous transcripts. The reduction in the expression of
a-SMA, Col1a1 and FN observed in the presence of miR-9-5p was
significantly attenuated after over-expression of TGFBR2 or NOX4
(Fig 3F). The percentage of inhibitory effect related to miR-9-5p
tended to be lower after transfection with plasmids containing
cDNAs for both proteins compared to their individual over-
expression (Fig 3F), suggesting that both genes are crucial in the
miR-9-5p-mediated anti-fibrotic effects. Whereas increased levels of
miR-9-5p had no effect on cell proliferation, cell viability, or apopto-
sis (Appendix Fig S4A–C), they reduced the migration (Fig 4A) and
invasion of ECM (Fig 4B) in response to TGF-b1, essential features
of the fibrotic phenotype [34,40]. These data suggested that
miR-9-5p can delay the TGF-b1-dependent transformation of lung
fibroblasts into myofibroblasts by regulating the TGF-b signaling
pathway. Consistently, increasing miR-9-5p levels attenuated
Smad3/4 activation (Fig 4C), Smad2 phosphorylation (Fig 4D) and
Smad2/3 nuclear translocation (Fig 4E) in response to TGF-b1
stimulation. The decrease in the phosphorylation of Smad2
observed in the presence of miR-9-5p was significantly abrogated
after over-expression of TGFBR2 (Fig 4F), suggesting that the inhibi-
tory effect of miR-9-5p on the TGF-b signaling pathway was, at least
in part, mediated by TGFBR2.
miR-9-5p is dysregulated in a mouse model of lung fibrosis and in
IPF patients
To determine the expression level of miR-9-5p in lungs of bleo-
mycin-treated mice, bleomycin was administrated orotracheally and
its effect analyzed after different time periods. Analysis by qRT–PCR
showed that miR-9-5p was significantly up-regulated after 7 days of
bleomycin administration, reaching the highest levels on day 14 and
returning to basal levels after 21 days of treatment (Fig 5A). A
similar temporal expression pattern was observed in the ECM
proteins, FN and Col1a1 (Fig 5B). In situ hybridization (ISH)
showed a dramatic increase of miR-9-5p in the fibrotic areas after
bleomycin-induced LF with no detectable signal in untreated control
mice (Fig 5C, lower panels). In contrast, there was only a minimal
background staining using scrambled probes, supporting the
specificity of miR-9-5p staining (Fig 5C, upper panels). Of notice,
lungs from patients with IPF also showed an increased expression of
miR-9-5p (Fig 5D). The extent of fibrosis in mouse and human lung
samples was confirmed by hematoxylin and eosin (H&E) and
Masson’s trichrome stainings (Figs EV3 and EV4). Taken together,
these data suggest that miR-9-5p may be involved in the pathogene-
sis of LF by regulating the transformation of fibroblasts into
myofibroblasts.
miR-9-5p prevents experimental lung fibrosis
To determine the potential role of miR-9-5p in the development of
experimental lung fibrosis, lentiviral vectors expressing a scramble
negative control construct (lenti-SC) or miR-9-5p (lenti-miR-9) were
orotracheally instilled in mice 4 days before bleomycin administra-
tion. The efficient delivery of lentivirus to the lung was monitored
by detecting the expression of the fluorescence marker GFP by
microscopy (Fig EV5A). Orotracheal lenti-miR-9 instillation
increased the expression levels of miR-9-5p up to 12-fold compared
to control mice (Fig EV5B). Lenti-miR-9 administration reduced the
mRNA elevated expression of a-SMA and ECM proteins, such as
Col1a1 and FN, elicited by bleomycin administration (Fig 6A). The
lenti-SC had no effects on bleomycin-induced LF (Fig EV5C).
Figure 2. miR-9-5p regulates TGFBR2 and NOX4 expression in human lung fibroblasts.
A qRT–PCR analysis of TGFBR2 expression in HFL-1 cells transfected with 40 nM pre-miR-NC (control) or pre-miR-9-5p for 48 h (n = 5).
B Western blot analysis (left) and quantification (n = 6) (right) of TGFBR2 protein levels in HFL-1 cells transfected as indicated in (A).
C Sequence of miR-9-5p and their base pairing (bars) with the BSs in the 30 UTR of human TGFBR2 mRNA. PMs are symbolized by red letters.
D Luciferase activity in HFL-1 cells co-transfected with psiCHECK2 containing WT or mutated 30 UTR sequences of human TGFBR2 and 40 nM of pre-miRs or miRNA
inhibitors (n = 3).
E qRT–PCR analysis of NOX4 expression in HFL-1 cells transfected as described in (A) and treated with 5 ng/ml TGF-b1 for the indicated times (n = 4).
F Western blot analysis (above) and quantification (below) of NOX4 expression in HFL-1 cells treated as described in (E) (n = 4).
G Localization of the three miR-9-5p predicted BSs in the 30 UTR of human NOX4 gene represented as described in (C).
H Luciferase activity as described in (D) with the WT or mutated 30 UTR sequences of human NOX4 gene (n = 3).
Data information: Data are shown as mean  SEM; two-tailed Mann–Whitney U-test; and *P < 0.05, **P < 0.01 compared to control cells, #P < 0.05 compared to its
corresponding negative control condition and ##P < 0.01 compared to WT 30 UTR sequence and pre-miR-9-5p co-transfected cells. a.u., arbitrary units; RLU, relative light
units.
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Pulmonary fibrosis, as assessed at days 0 and 14 after bleomycin
administration, was determined in mice treated with lenti-SC or
lenti-miR-9. H&E staining showed a dramatic attenuation of
bleomycin-induced LF in mice pre-treated with lenti-miR-9 (Fig 6B,
upper panels). Masson’s trichrome staining confirmed this finding
(Fig 6B, middle panels). Similarly, pre-treatment with lenti-miR-9
Figure 2.
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prevented the accumulation of myofibroblasts in bleomycin-treated
lungs, as demonstrated by immunohistochemistry staining with
a-SMA antibody (Fig 6B, lower panels). A semi-quantitative evalua-
tion demonstrated that lungs of lenti-miR-9 pre-treated mice
displayed lower levels of collagen content (depicted by Masson’s
trichrome staining) (Fig 6C) and less myofibroblasts (positive
a-SMA cells) (Fig 6D) compared to lungs of lenti-SC pre-treated
mice. In keeping, the total fibrotic area, evaluated by quantifying
Masson′s trichrome staining, was significantly lower in lungs of
mice receiving the lenti-miR-9 compared to controls (Fig 6E). These
results indicate that miR-9-5p not only decreases experimental
pulmonary fibrosis but also that it plays a significant preventive role
in the induction of myofibroblast differentiation. Increasing miR-9-5p
levels by lentiviral infection reduced TGFBR2 and bleomycin-
induced NOX4 mRNA expression (Fig 7A and B), in consistence
with in cellulo observations. Immunohistochemistry staining of
TGFBR2 in lungs of mice pre-treated with lenti-miR-9 exhibited
lower levels of TGFBR2 after bleomycin administration, confirming
the negative regulation of TGFBR2 by miR-9-5p also in vivo (Fig 7C,
upper panels). Because miR-9-5p regulated TGF-b1 signaling events
in human lung fibroblasts in cellulo, we wanted to prove if the same
regulation also occurred in vivo. As expected, there was an attenua-
tion in the phosphorylation of Smad2 induced by bleomycin in lungs
of mice pre-treated with lenti-miR-9 (Fig 7C, lower panels), thus
supporting that miR-9-5p interferes with a crucial process in TGF-b
signaling inherent to the fibrotic response [31,41].
Reduction of miR-9-5p expression enhances experimental
lung fibrosis
To further confirm the anti-fibrotic role of miR-9-5p, mirVana
miRNA inhibitor-9-5p was used to modulate miR-9-5p expression
in vivo. A decrease of more than 60% in the expression of miR-9-5p
was observed after orotracheal miRNA inhibitor-9-5p instillation
compared to control mice (Fig EV5D). miRNA inhibitor-9-5p admin-
istration significantly increased the bleomycin-induced mRNA
expression of Col1a1 and FN (Fig 8A). Pulmonary fibrosis was
determined in mice treated with miRNA inhibitor NC or miRNA
inhibitor-9-5p 4 and 2 days before bleomycin administration. H&E
staining showed an exacerbation of bleomycin-induced LF in mice
with reduced miR-9-5p expression (Fig 8B, upper panels). Masson’s
trichrome staining confirmed this finding (Fig 8B, middle panels).
Similarly, pre-treatment with miRNA inhibitor-9-5p enhanced
the accumulation of myofibroblasts (a-SMA positive cells) in
bleomycin-treated lungs (Fig 8B, lower panels). Lungs of miRNA
inhibitor-9-5p pre-treated mice displayed higher levels of collagen
content (Fig 8C) and less myofibroblasts (Fig 8D) compared to
lungs of miRNA inhibitor NC pre-treated mice. The amplification of
the fibrotic response when miR-9-5p expression was diminished
supports the preventive role of miR-9-5p in LF.
miR-9-5p is up-regulated in peritoneal dialysis patients and
prevents mesothelial to mesenchymal transition in peritoneal
mesothelial cells
PMCs that undergo an MMT are characterized by changes in cell
morphology, a disruption of tight junctions and a loss of cell
polarity acquiring stronger migratory and invasive capacities, which
allow these cells to invade the submesothelial stroma, where they
contribute to PF and angiogenesis and ultimately lead to peritoneal
membrane failure [15,42,43]. TGF-b1 is the main regulator of MMT
in PMCs [44]. Given the potential regulatory role of miR-9-5p in LF,
we sought to study if this action could be extended to PF. Human
MCs isolated from effluents in the dialysis fluid of patients under-
going continuous PD were classified in epithelioid (epith) and non-
epithelioid (non-epith) MCs according to their morphological
features (Appendix Fig S5A) and mRNA expression levels of
E-cadherin (CDH1), Col1a1 and FN (Appendix Fig S5B). Non-epith
MCs showed increased expression levels of miR-9-5p compared to
epith MCs (Fig 9A). Additionally, MCs isolated from effluents
exhibited increased expression of miR-9-5p compared with MCs
derived from omentum (Fig 9A). miR-9-5p was also up-regulated in
omentum-derived MCs after TGF-b1 treatment (Fig 9B). Furthermore,
over-expression of miR-9-5p in omentum-derived MCs abrogated
TGF-b1-induced expression of a-SMA, Col1a1 and FN (Fig 9C),
similar to lung fibroblasts. Consistently, up-regulation of miR-9-5p
decreased a-SMA protein levels in omentum-derived MCs (Fig 9D)
and reduced their invasive capacity into the ECM in response to
TGF-b1 (Fig 9E), an essential feature of their contribution to PF.
Increasing miR-9-5p levels reduced TGFBR2 and TGF-b1-induced
NOX4 mRNA expression (Fig 9F and G), in consistence with our
previous observations.
Discussion
In this study, miR-9-5p has been identified as a novel miRNA
included in two distinct, but closely related, sets of microRNAs that
Figure 3. miR-9-5p inhibits TGF-b1-induced transformation of human lung fibroblasts into myofibroblasts.
A qRT–PCR analysis of a-SMA (n = 4), Col1a (n = 3) and FN (n = 3) expression levels in HFL-1 cells transfected with 40 nM pre-miR-NC (control) or pre-miR-9-5p
and treated with 5 ng/ml TGF-b1 for the indicated times.
B, C Protein levels (above) of a-SMA (n = 4) (B) and FN (n = 3) (C) in HFL-1 cells described in (A). Quantification of protein expression is shown below. a.u., arbitrary
units.
D, E Fluorescence microscopy images of HFL-1 cells stained with specific antibodies against a-SMA (D, middle panels) and FN (E, middle panels) after transfection as
described in (A) and TGF-b1 treatment for 48 h (n = 3). Nuclei were stained with DAPI (blue). Scale bars: 100 lm.
F Bar graph represents percentage (%) of inhibitory effect of miR-9-5p on a-SMA, Col1a1 and FN expression after over-expression of TGFBR2, NOX4 or both. HFL-1
cells were transfected with 3 lg pCMV5-TGFBR2, 3 lg pCMV6-NOX4 or 3 lg of each plasmid and 40 nM pre-miR-9-5p and treated with 5 ng/ml TGF-b1 for 24 h
(n = 4). Control cells were transfected with 3 lg pCMV5 and 3 lg pCMV6.
Data information: All bar graphs show mean  SEM; two-tailed Mann–Whitney U-test; *P < 0.05, **P < 0.01 compared to control cells and #P < 0.05, ##P < 0.01
compared to its corresponding negative control time point.
Source data are available online for this figure.
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have been recently defined, the redoximiRs, redox sensitive micro-
RNAs [30], and the fibromiRs, miRNAs that show an aberrant
expression during the development of fibrosis [26]. Our results
support a model in which increased ROS, a common pathological
feature of human fibrosis [45] on one side, and TGF-b1 actions,
including TGF-b1 ROS production, on the other induce an increase
in the levels of miR-9-5p (Fig 10). Over-expression of miR-9-5p in
lung fibroblasts prevented myofibroblast differentiation, activation,
migration and invasion while blocking the TGF-b1-dependent effects
through the inhibition of the Smad-dependent pathway. Smad3/4
Figure 3.
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activation, Smad2 phosphorylation and Smad2/3 nuclear transloca-
tion are conspicuously delayed in lung fibroblasts with increased
levels of miR-9-5p. Exogenously enhanced expression of TGFBR2
attenuated the inhibitory effect of miR-9-5p on TGF-b1-induced
Smad2 phosphorylation, indicating that TGFBR2 was important for
miR-9-5p inhibition of the TGF-b-mediated fibrogenesis signaling
pathway. Synthesis and deposition of ECM were also prevented by
over-expressing miR-9-5p. This protective role for LF was confirmed
Figure 4. miR-9-5p inhibits the TGF-b1-induced fibrogenic pathway in human lung fibroblasts.
A Fluorescence images (left) and quantification (n = 3) (right) of migration in HFL-1 cells transfected with either 40 nM pre-miR-NC (control) or pre-miR-9-5p in
response to TGF-b1 for the indicated times. Nuclei were stained with DAPI (blue). Scale bar: 100 lm.
B Fluorescence images (left) and quantification (n = 3) (right) of collagen matrix invasion in HFL-1 cells transfected with either 40 nM pre-miR-NC or pre-miR-9-5p in
response to TGF-b1 for 48 h. Nuclei were stained with DAPI (blue). Scale bar: 100 lm.
C Luciferase activity of the reporter construct in HFL-1 cells co-transfected with 40 nM pre-miR-NC or pre-miR-9-5p and treated with 5 ng/ml TGF-b1 for 24 h (n = 3).
D Western blot analysis (left) and quantification (n = 4) (right) of pSmad2 protein levels in HFL-1 cells transfected as described in (A) and treated with 5 ng/ml TGF-b1
for the indicated times. a.u., arbitrary units.
E Fluorescence microscopy images of HFL-1 cells stained with specific antibodies against Smad2/3 (green) after indicated treatments (n = 3). Nuclei were stained with
DAPI (blue) and F-actin was stained with phalloidin (red). Scale bar: 100 lm.
F Bar graph represents percentage (%) of inhibitory effect of miR-9-5p on Smad2 phosphorylation after over-expression of TGFBR2 in HFL-1 cells transfected with 3 lg
pCMV5-TGFBR2 (TGFBR2) and 40 nM pre-miR-9-5p and treated with 5 ng/ml TGF-b1 for 15 min (densitometric analysis from four separate experiments). Control cells
were transfected with 3 lg pCMV5.
Data information: Data are shown as mean  SEM; two-tailed Mann–Whitney U-test; *P < 0.05 compared to control cells and #P < 0.05 compared to its corresponding
negative control time point.
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in mice with enhanced expression of miR-9-5p. By contrast, loss-of-
function approaches where miR-9-5p was inhibited resulted in an
enhanced fibrogenic phenotype, both in cells and whole animal
studies. Finally, the increased abundance of miR-9-5p in IPF
specimens and in cells from PD patients is highly suggestive of a
possible implication of this miRNA in the setting of human fibrosis.
TGF-b itself can alter the expression of numerous miRNAs. It has
been reported that the signal transducers of the TGF-b signaling
cascade, SMADs, not only regulate gene expression at the level of
transcription but also control Drosha-mediated miRNA processing
[46,47]. Our results support the idea that TGF-b1 increased miR-9-5p
expression levels in lung fibroblasts by inducing pri-miR-9 transcrip-
tion. In humans, miR-9 can be generated by the processing of three
different miR-9 primary transcripts encoded by distinct genes
located in different chromosomes (1, 5 and 15). Inspection of the
genomic sequence of miR-9 genes by using the BLAST (Basic Local
Alignment Search Tool) algorithm [48] modified with ad hoc Python
scripts identified the presence of at least two Smad-binding elements
(SBEs) [33,49] in the putative promoter region of miR-9-1 and at
least another two for miR-9-3, indicating that both genes are poten-
tially regulated by TGF-b1. This observation turned miR-9 into a
novel TGF-b1-target gene. However, the regulation of miR-9-5p
processing by SMADs cannot be excluded and needs to be further
investigated. Our results also indicate that TGF-b1 increases miR-9-5p
expression levels by a ROS-dependent mechanism.
Our data support the existence of an auto-regulatory feedback
loop between TGF-b1 and miR-9-5p. We propose that TGF-b1
triggers simultaneous pro- and anti-fibrotic signals, and hence,
miR-9-5p would contribute to limit fibrogenesis by counteracting the
cascade of pro-fibrotic stimuli elicited by TGF-b1, including ROS, in
the context of an homeostatic response. It is reasonable to assume
that levels of miR-9-5p induced by TGF-b1 or bleomycin are low
compared to those reached after exogenous miR-9-5p administra-
tion. As a consequence, the balance toward fibrosis would prevail,
further leading to failure in the prevention of myofibroblast transfor-
mation and full establishment of a fibrotic phenotype. Participation
in feedback loops is a common pathogenic mechanism of fibromiRs
[26]. In most cases, changes in fibromiR expression inhibit negative
Figure 5. miR-9-5p is up-regulated in lungs from both bleomycin-treated mice and IPF patients.
A, B qRT–PCR analysis of miR-9-5p (A), FN and Col1a1 (B) expression in lungs of mice after orotracheal bleomycin administration (1.5 U/kg body weight in 40 ll saline)
for the indicated times (n = 6 mice per group). *P ˂ 0.05, **P ˂ 0.01 compared to day 0.
C Microphotographs of ISH showing miR-9-5p expression (purple, lower panels) in mouse lung samples at days 0 and 14 after bleomycin instillation (n = 3 mice per
group). ISH with scrambled probes are shown in the upper images. Scale bar: 50 lm.
D qRT–PCR analysis of miR-9-5p expression levels in three histologically normal lungs (controls) and in seven lungs from IPF patients. *P ˂ 0.05 compared to control
lungs.
Data information: Bar graphs show mean  SEM; two-tailed Mann–Whitney U-test.
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Figure 6. miR-9-5p prevents pulmonary fibrosis in mice.
A qRT–PCR analysis of a-SMA, Col1a1 and FN expression in lungs from mice administered 1 × 106 i.f.u. of lenti-SC (control) or lenti-miR-9 for 4 days followed by
orotracheal bleomycin administration (1.5 U/kg body weight in 40 ll saline) or saline for 14 days (n = 4 mice per group).
B Microphotographs of H&E (upper panels) and Masson’s trichrome staining (middle panels) and a-SMA expression (lower panels) from lung sections of mice treated
as described in (A) (n = 4 mice per group). Scale bars: 100 lm.
C, D Semiquantitative determination (grade 0 to 3) of the collagen content (C) and the quantity of myofibroblasts (D) in lung tissue samples from mice treated as
described in (A) (n = 5 mice per group). Each mouse is represented by a symbol, dots represent lenti-SC and squares represent lenti-miR-9-treated mice,
respectively.
E Total area of lung fibrosis (mm2) in lung sections from mice treated as described in (A) (n = 4 mice per group).
Data information: Data are shown as median  SEM; two-tailed Mann–Whitney U-test; *P ˂ 0.05 compared to mice given control lentivirus and saline-treated and
#P < 0.05 compared to mice given control lentivirus and bleomycin-treated.
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fibrogenic or induce pro-fibrogenic mechanisms and cause a positive
feed-forward loop that perpetuates the activation of a fibrogenic
pathway, thus sustaining the pro-fibrotic phenotype [29]. In the
context of LF, this fact is particularly well illustrated by miR-21,
which is up-regulated in the lungs of bleomycin-treated mice and IPF
patients and promotes TGF-b-induced fibrogenic activation of
pulmonary fibroblasts by targeting Smad7 [28]. By contrast, the
expression of several members of the miR-29 family has been shown
to be reduced in lungs of bleomycin-treated animals and IPF patients
and it has been involved in inhibiting ECM protein synthesis, thus
suggesting an anti-fibrotic function [50,51]. In keeping, let-7d has
been found to be decreased in IPF lungs and this reduction has been
related to the dramatic phenotypic changes occurring in the alveolar
epithelia of these patients [51]. Although less common, fibromiRs
can participate in negative feedback loops to promote fibrosis [52].
TGFBR2 is a transmembrane serine/threonine kinase receptor
necessary for TGF-b1 signal transduction [53] and has been impli-
cated in lung development and pulmonary disease [35]. TGF-b1
induces NOX4 mRNA and protein expression in lung fibroblasts and
NOX-4-dependent H2O2 generation is required for myofibroblast dif-
ferentiation, synthesis of ECM proteins and contractility mediated
by TGF-b1. NOX4 has been further invoked as an important player
in the development of LF [10,54]. TGFBR2 and NOX4 are proposed
to represent direct targets of miR-9-5p not only by in silico analysis
and further molecular validation but also by data demonstrating
reduced action of the miRNA in the presence of exogenously
enhanced expression of these proteins. Our results are consistent
with the notion that miR-9-5p causes degradation of TGFBR2 and
TGF-b1-induced NOX4 mRNAs and also interferes with TGFBR2 and
TGF-b1-induced NOX4 protein translation. The ability of miR-9-5p
to reduce the levels of both target genes in lung fibroblasts consti-
tutes one of the plausible mechanisms to explain the anti-fibrotic
action of miR-9-5p. However, it is possible that other targets of
miR-9-5p within the signaling pathways related to TGF-b and/or
ECM synthesis also contribute to this outcome. Indeed, we demon-
strated that over-expression of miR-9-5p results in the repression of
additional genes belonging to the TGF-b pathway. For example, the
Col1a1 gene has two poorly conserved BSs for miR-9-5p, as the
TargetScan database predicts, but whether or not it is a direct target
of this miRNA remains to be proven. Additionally, the effects in the
expression reduction of other predicted miR-9-5p targets will need
to be tested in future studies, especially those related to the TGF-b1
signaling pathway, like TGFBR1, Smad4 or integrins because of
their essential role in lung fibrosis development [2,7,55–57].
Figure 7. miR-9-5p regulates TGFBR2 and NOX4 expression and inhibits Smad2 phosphorylation in mouse lungs.
A qRT–PCR analysis of TGFBR2 expression in lungs from mice administered lenti-SC (control) or lenti-miR-9 (1 × 106 i.f.u.) (n = 4 mice per group).
B qRT–PCR analysis of NOX4 expression in lungs from mice given lenti-SC (control) or lenti-miR-9 (1 × 106 i.f.u. per mouse) for 4 days followed by orotracheal
bleomycin administration (1.5 U/kg body weight in 40 ll saline) or saline for 14 days (n = 4 mice per group).
C Microphotographs of TGFBR2 and pSmad2 expression in mouse lung samples described in (B) (n = 4 mice per group). Scale bars: 100 lm.
Data information: Bar graphs show mean  SEM; two-tailed Mann–Whitney U-test; *P ˂ 0.05 compared to saline-treated mice administered lenti-SC and #P ˂ 0.05
compared to bleomycin-treated mice administered lenti-SC.
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Figure 8. miR-9-5p inhibition exacerbates pulmonary fibrosis in mice.
A qRT–PCR analysis of Col1a1 and FN expression in lungs from mice administered miRNA inhibitor NC (control) or miRNA inhibitor-9-5p (7 mg/kg body weight in
40 ll saline) 4 and 2 days before orotracheal instillation of bleomycin (1.5 U/kg body weight in 40 ll saline) or saline for 10 days (n = 3–6 mice per group).
B Microphotographs of H&E (upper panels) and Masson’s trichrome staining (middle panels) and a-SMA expression (lower panels) from lung sections of mice treated
as described in (A) (n = 3–7 mice per group). Scale bars: 100 lm.
C, D Semiquantitative determination (grade 0 to 3) of the collagen content (C) and the quantity of myofibroblasts (D) in lung tissue samples from mice treated as
described in (A) (n = 5–7 mice per group). Each mouse is represented by a symbol, dots represent miRNA inhibitor NC and squares represent miRNA inhibitor-9-5p-
treated mice, respectively.
Data information: Data are shown as mean  SEM; two-tailed Mann–Whitney U-test; *P ˂ 0.05, **P ˂ 0.01 compared to mice given control miRNA inhibitor and saline-
treated, and #P < 0.05, ##P < 0.01 compared to mice given control miRNA inhibitor and bleomycin-treated.
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Concomitantly, other miR-9-5p-predicted target genes implicated in
additional signaling activated during LF, such as the WNT/b-catenin
pathway [58], or related to the inflammatory immune response
[2,7] should be explored. Finally, some studies have suggested an
alternative miRNA mechanism for silencing gene expression by
binding to promoter regions in human cells [59,60]. microPIR soft-
ware (microRNA-Promoter Interaction Resource, http://www4a.
biotec.or.th/micropir/) [61] predicted the existence of miR-9-5p BSs
in the promoters of TGF-b-related genes, Smads, TGFBRs, NOX4
and TGF-b, and also in key fibrotic markers, a-SMA, or Col1a1 (data
not shown). This suggests that miR-9-5p could also carry out its
anti-fibrotic role by affecting the expression of some of these genes,
although this hypothesis needs to be confirmed.
The involvement of dysregulated TGF-b signaling is a well-
established pathogenetic mechanism in IPF [7]. Our data strongly
suggest that miR-9-5p controls this process in an attempt to reduce
Figure 9.
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the excessive pro-fibrotic signals promoted by TGF-b. However,
although mice with miR-9-5p over-expression exhibited attenuation
of LF, detailed histological analysis suggested that it failed to
entirely abrogate the fibrotic phenotype. In spite of a miR-9-5p-
induced decrement in the expression of TGFBR2 and NOX4
and reduced levels of Smad2 phosphorylation, indicating down-
regulation of the TGF-b pathway, slightly increased matrix deposi-
tion and moderately enhanced a-SMA and ECM gene expression
were still observed in lungs from animals after bleomycin instilla-
tion. Potential explanations for this limited action include the exis-
tence of TGF-b-independent pro-fibrogenic stimuli perduring in
resident fibroblasts, alternative TGF-b signaling mediated by recep-
tors other than TGFBR2 and/or signaling through molecules
different from Smads. In addition, matrix generation by non-resident
fibroblasts was not ruled out.
In the lung, as in other organs, the origin of myofibroblasts is still
unclear and a matter of controversy [37]. Some authors have
proposed that they can emerge from mesoderm-derived pleural MCs
in a process known as MMT [62,63]. We have extended the action
of miR-9-5p precisely to this scenario and results obtained in PMCs
confirmed that miR-9-5p also plays a significant preventive role in
the TGF-b1-mediated transformation of MCs into fibrogenic
myofibroblasts. Increasing miR-9-5p levels significantly reduced
the invasive capacity of MCs, this representing one mechanism
preventing the accumulation of MC-derived myofibroblasts in
the submesothelial compact zone of the peritoneum, therefore
protecting it from the initiation of the fibrotic process. Noteworthy,
miR-9-5p over-expression also decreased TGFBR2 and TGF-b1-
induced NOX4 levels. This may represent a potential mechanism
contributing to the anti-fibrotic role of miR-9-5p in PMCs. The
increased expression of miR-9-5p observed in human non-epith
compared to epith MCs reinforces the protective role for miR-9-5p
in the development of PF. The capacity of miR-9-5p to inhibit the
pro-fibrogenic transformation induced by TGF-b1, not only in
pulmonary fibroblasts but also in PMCs and the increased miR-9-5p
expression in IPF patients and in omentum-derived MCs of PD
patients also confer miR-9-5p the potential of playing a more
general counter-regulatory role in human organ fibrosis, which
should be addressed in other pathological contexts.
Importantly, recent studies have emerged demonstrating that
miRNAs are also externalized from cells and transported into body
fluids, thereby shuttling genetic information from a donor to a
recipient cell [64–66]. Although the secretory mechanism remains
essentially unknown, circulating miRNAs represent not only
potential non-invasive biomarkers for many diseases but also tools
to monitor their onset and progress as well their therapeutic response
[65,67]. miRNAs secreted by immune cells, stem cells, adipocytes
and blood cells have recently been identified [64]. It has been shown
that cancer cells release microvesicles that contain miR-9 [68]. The
secretion of miR-9-5p in a fibrotic context could pave the way to
establish it as a novel serum biomarker for the diagnosis and progno-
sis in organ fibrosis. Currently, we believe that our results purport
miR-9-5p as a potential therapeutic tool for human organ fibrosis.
Materials and Methods
Cell culture and treatments
The human fetal lung fibroblast cell line HFL-1 (CCL-153) was
obtained from American Type Culture Collection (ATCC, VA). Cells
were grown in F12K medium (ATCC) containing 10% (vol/vol) FBS
(HyClone Laboratories, Logan, UT) and 1% (vol/vol) penicillin/
streptomycin (Gibco, Rockville, MD) at 37°C in 5% CO2. For treat-
ments, cells were serum starved overnight and then incubated with
100 lM hydrogen peroxide (H2O2) (Sigma-Aldrich, St. Louis, MO),
5 ng/ml recombinant human transforming growth factor beta 1
(TGF-b1) (R&D Systems, Minneapolis, MN), 20,70-dichlorofluorescein
Figure 10. Regulation of fibrogenesis by miR-9-5p.
ROS and TGF-b1 induce miR-9-5p expression. Over-expression of miR-9-5p in
lung fibroblasts and omentum-derived MCs blocks TGFBR2 and NOX4
expression, thus preventing myofibroblast differentiation, ECM deposition and
organ fibrogenesis.
Figure 9. miR-9-5p is up-regulated in non-epith effluent-derived MCs from PD patients, attenuates TGF-b1-induced fibrogenesis and regulates TGFBR2 and
NOX4 expression in omentum-derived MCs.
A qRT–PCR analysis of miR-9-5p expression in omentum-derived MCs (n = 3) epith (n = 5) and non-epith (n = 4) effluent-derived MCs. *P ˂ 0.05 compared to
omentum-derived MCs and #P ˂ 0.05 compared to epith effluent-derived MCs.
B qRT–PCR analysis of miR-9-5p expression in omentum-derived MCs treated with 5 ng/ml TGF-b1 for 48 h (n = 3). *P ˂ 0.05 compared to untreated cells.
C qRT–PCR analysis of a-SMA, Col1a1 and FN in omentum-derived MCs transfected with 40 nM pre-miR-NC (control) or pre-miR-9-5p and treated with 5 ng/ml
TGF-b1 for 48 h (n = 3). *P < 0.05 compared to negative control-transfected cells and #P < 0.05 compared to the corresponding negative control time point.
D Western blot analysis (left) and quantification (right) of a-SMA protein levels in cells treated as described in (C) (n = 3). a.u., arbitrary units. *P < 0.05 compared to
negative control-transfected cells and #P < 0.05 compared to the corresponding negative control time point.
E Fluorescence images (left) and quantification (right) of collagen matrix invasion in omentum-derived MCs transfected with either 40 nM pre-miR-NC or pre-miR-9-5p in
response to TGF-b1 for 24 h (n = 3). Nuclei were stained with DAPI (blue). Scale bar: 100 lm.
F qRT–PCR analysis of TGFBR2 expression in omentum-derived MCs transfected with 40 nM of pre-miR-NC (control) or pre-miR-9-5p for 48 h (n = 3).
G qRT–PCR analysis of NOX4 expression in omentum-derived MCs treated as described in (C) (n = 3).
Data information: Bar graphs show mean  SEM; two-tailed Mann–Whitney U-test; *P < 0.05 compared to negative control-transfected cells and #P < 0.05 compared
to the corresponding negative control time point.
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diacetate (DCFH-DA, Invitrogen, Carlsbad, CA), polyethyleneglycol
(PEG) (Sigma-Aldrich), and 100 units/ml PEG-catalase (Sigma-
Aldrich) for the indicated times. Human mesothelial cells (MCs)
were isolated from omentum samples of patients undergoing unre-
lated abdominal surgery or from effluents of PD patients as previ-
ously described [69]. MCs were cultured in Earle’s M199 medium
(Sigma-Aldrich) supplemented with 20% FBS, 2% Hepes 1 M
(Sigma-Aldrich), 50 U/ml penicillin/50 lg/ml streptomycin and 2%
Biogro-2 (Biological Industries, Beit Haemek, Israel). The purity of
MCs cultures was determined by the expression of intercellular
adhesion molecule (ICAM)-1, calretinin and cytokeratins. MCs
cultures were negative for von-Willebrand factor and CD45, ruling
out any contamination by endothelial cells or macrophages [69,70].
To induce MMT in vitro, omentum-derived MCs were treated for
48 h with 5 ng/ml of TGF-b1 (R&D Systems). MCs isolated from PD
patients were classified into two groups: epithelioid (epith) (n = 5)
and non-epithelioid (non-epith) (n = 4) MCs [12,71,72].
Transfection of miRNA precursors and inhibitors
Cells at 60% confluence were transfected with 40 nM of either pre-
miRTM miRNA precursor of miR-9-5p (pre-miR-9-5p) (AM17100,
Ambion, Carlsbad, CA) or miR-9 inhibitor (miRNA Inhibitor-9)
(4464088, Ambion) using Lipofectamine 2000 (Invitrogen). In all
experiments an equal concentration of a non-targeting sequence
Pre-miRTM miRNA Precursor Negative Control #1 (pre-miR-NC)
(AM17110, Ambion) or miRNA Inhibitor Negative Control #1
(miRNA Inhibitor NC) (4464079, Ambion) was used.
Transfection of plasmids
HFL-1 cells were used for transient cDNA expression. Transfections
(3 lg of plasmid) were performed by electroporation using the Elec-
tro Cell Manipulator 600 (BTX, San Diego, CA). The pCMV5 empty
vector and the pCMV5-TGFBR2 expression vector were kindly
provided by Dr. Carmelo Bernabe´u (Centro de Investigaciones
Biolo´gicas, CSIC, Madrid, Spain). An expression vector containing
the human NOX4 open reading frame (pCMV5-NOX4) was
purchased from Origene (Rockville, MD). The pCMV6-AC-GFP
empty vector was also purchased from Origene (Rockville, MD).
The efficiency of transfection was ~20–30%. The over-expression of
TGFBR2 and NOX4 was confirmed by qRT–PCR (primer sequences
used for mRNA quantification are shown in Table EV5).
RNA extraction
Total RNA was isolated from cells and lung tissue using the
miRNeasy Mini Kit (QIAGEN, Valencia, CA). For RNA extraction in
paraffin-embedded human samples, miRNeasy FFPE Kit (QIAGEN)
was used. RNA quantity and quality were determined at 260 nm by
a Nanodrop spectrophotometer.
microRNA profiling
Taqman miRNA low-density arrays (TLDAs) (Applied Biosystems,
Foster City, CA) were selected as the platform for microRNA profil-
ing. This platform consists of a two-card set (Cards A and B) for a
total of 754 unique assays specific for human miRNAs present in the
Sanger miRBase v14 (http://microrna.sanger.ac.uk). After RNA
extraction, miRNA present in 500 ng of total RNA was subjected to
reverse transcription using the Megaplex RT Primer Human Pool A
and B and the Taqman microRNA reverse transcription kit (Applied
Biosystems) according to the manufacturer’s instructions. The resul-
tant cDNAs were analyzed using Human Card Set v3. Reactions
were incubated in an Applied Biosystems 7900HT Fast Real-Time
PCR system in 384-well TLDAs using the manufacturer’s recom-
mended protocol.
Statistical analysis of TLDAs data
The ABI TaqMan SDS v2.2 software was utilized to obtain raw thresh-
old cycle (Ct) value for each miRNA. Only miRNAs with a Ct ≤ 36
were included in the analyses. The Ct data were analyzed with the
StatMiner 4.2.8 software (Integromics; Madrid, Spain). Mammalian
small nuclear RNAU6 (snRNAU6) was used as endogenous control
gene for normalizing gene expression levels after application of the
geNorm [73] and NormFinder [74] algorithms. The delta Ct (DCt)
value was calculated by normalizing Ct values to the endogenous
housekeeping snRNAU6. The heat map was generated by the real-
time PCR data presented as DCt. Heat map scale bars indicate DCt
values and red and green colors depict low and high expression
levels, respectively. miRNAs showing similar DCt values were
grouped by hierarchical clustering. The delta delta Ct (DDCt) value
was calculated by subtracting the DCt of the reference sample (control
cells) from the DCt of each H2O2-treated sample. Relative quan-
tification (RQ) or fold change of each miRNA was generated using the
2DDCt method [75]. Differentially expressed miRNAs were identified
by the parametric Limma test [76]. To take the multiple hypotheses
testing into account, P-values were adjusted (adj.) using the
Benjamini–Hochberg false discovery rate (FDR) correction [77].
Results were graphed in a volcano plot and miRNAs with Benjamini–
Hochberg adj. P-values < 0.05 (Table EV1) were highlighted.
Quantification of miRNA expression
Quantification of miR-9-5p expression was performed using the
miRCURY Locked Nucleic Acid (LNA) Universal RT microRNA PCR
(Exiqon, Denmark). Following reverse transcription (RT), the cDNA
template was amplified using microRNA-specific LNA primers for
mature miR-9-5p (204513, Exiqon, Denmark). qRT–PCR was
performed in a 96-well Bio-Rad CFX96 RealTime PCR System with a
C1000 Thermal Cycler using iQTM SYBR Green Supermix (Bio-Rad,
Hercules, CA). A Ct value for triplicate wells was obtained from each
amplification curve using the CFX Manager Bio-rad software (Bio-
Rad). Ct values were normalized to the endogenous control
snRNAU6. Relative miRNA expression was determined using the
2DDCt method [75].
Quantification of pri-miRNAs expression
Quantitative expression studies of primary miR-9 (pri-miR-9) tran-
scripts were performed using TaqMan Pri-miRNA Assays (Applied
Biosystem). cDNA was obtained using the High Capacity RNA-to-
cDNA Kit (Applied Biosystem) and amplified using specific primers
for pri-miR-9-1, pri-miR-9-2, or pri-miR-9-3 (Hs03303201_pri,
Hs03303202_pri, and Hs03293595_pri, Applied Biosystem) in separate
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reactions. qRT–PCR was performed in an Applied Biosystems 7900HT
Fast RT–PCR system. The expression level of each pri-miR was calcu-
lated according to the 2DDCt method [75], using the GAPDH gene as
an internal control. All reactions were performed in triplicate.
Analysis of mRNA expression
RT was carried out with 500 ng of total RNA using the iScriptTM
cDNA Synthesis kit (Bio-Rad). qRT–PCR was carried out with the
iQTMSYBR Green Supermix (Bio-Rad), using a 96-well Bio-Rad
CFX96 RT–PCR System with a C1000 Thermal Cycler (Bio-Rad). A
Ct value was obtained from each amplification curve using CFX96
analysis software provided by the manufacturer. Relative mRNA
expression was determined using the 2DDCt method [75]. GAPDH
gene was used for normalization purposes. The primer sequences
used for mRNA quantification are shown in Table EV5.
microRNA target prediction bioinformatics tools and functional
clustering analyses
The online microRNA databases and target prediction tools Target-
Scan (http://www.targetscan.org), miRanda (http://www.microrna.
org) and miRwalk (http://www.umm.uni-heidelberg.de/apps/zmf/
mirwalk/) were used to identify potential miR-9-5p targets
(Table EV2). These were selected for Functional Annotation Cluster-
ing in the bioinformatics Database for Annotation, Visualization and
Integrated Discovery (DAVID) v6.7 (http://david.abcc.ncifcrf.gov/)
[78] using the Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway databases. Enrichment score was reported as the minus log
transformation of the geometric mean of P-values (modified Fisher’s
exact test). The P-value was corrected for multiple hypothesis testing
with the Benjamini–Hochberg FDR algorithm [77]. Terms with a
corrected P < 0.05 were considered significant. This same list was
used for comparison with genes related to the “TGF-b signaling
pathway” (Tables EV3 and EV4).
Luciferase assays and site-specific mutagenesis
To characterize the candidate sites, cDNA fragments corresponding
to the three prime untranslated regions (30 UTRs) of human TGFBR2
and NOX4 were amplified by RT–PCR from genomic DNA of HFL-1
cells. For site-specific mutagenesis, the regions in the 30 UTRs
complementary to the seed sequence of miR-9-5p were mutated
using the Multisite-QuikChange directed mutagenesis kit (Strata-
gene, La Jolla, CA) and primers used are shown in Table EV6. Point
mutations (PM) are a two-base change in the seed sequence for
miR-9-5-p. For luciferase assays, WT or mutant 30 UTRs were cloned
into the psiCHECK-2 vector (Promega, Madison, WI). Inserts were
sequenced to confirm appropriate structure. The activity of Renilla
luciferase was normalized by the internal firefly luciferase activity.
HFL-1 cells were transiently co-transfected with 125 ng psiCHECK-
2/TGFBR2 or psiCHECK-2/NOX4 reporter plasmids and 40 nM pre-
miRs by triplicate. Luciferase assays were performed 24 h later
using the Dual-Luciferase reporter system (Promega, Madison, WI).
The Renilla and firefly luciferase signals were detected using a
Glomax multidetection system (Promega, Madison). Smad-specific
luciferase reporter (CAGA-luc) was a generous gift from Dr. Aris
Moustakas (Biomedical Center Uppsala, Sweden) [33]. Transient
transfection experiments were performed with HFL-1 cells and
promoter activity was estimated by luminometry as described previ-
ously using pRL-CMV plasmid (a Renilla luciferase under the control
of the CMV promoter) for normalization purposes [79].
Analysis of intracellular ROS by flow cytometry
HFL-1 cells were incubated with 10 lM DCFH-DA for 15 min at
37°C in humidified air with 5% CO2 at 37°C. After incubation, the
single cell fluorescence of 10,000 cells for each sample was
measured using a BD FACSCantoTM II High Throughput Sampler
flow cytometer (Becton Dickinson Bioscience, Franklin Lakes, NJ).
All the data analyses were performed using Flow Jo v6.4.1 software
(Treestar, Ashland, OR).
Western blot analysis and antibodies
Briefly, cells were washed with PBS, homogenized and lysed in
150 ll RIPA buffer containing 150 mM NaCl, 0.1% SDS, 1% sodium
deoxycholate, 1% NP-40 and 25 mM Tris–HCl pH 7.6, in the presence
of protease (Complete, Roche Diagnostics, Mannheim, Germany) and
phosphatase inhibitors (Sigma-Aldrich). Cells were harvested by
scraping and the samples were clarified by centrifugation at 10,000 g
for 15 min at 4°C. Protein concentrations were determined by the
BCA Protein Assay Kit (Thermo Scientific, Rockford, IL). Equal
amounts of protein (10–50 lg) from the total extract were separated
on 8–10% SDS–polyacrylamide gels and transferred onto nitrocellu-
lose blotting membranes (GE Healthcare, Germany) at 12 V for
20 min in a semi-dry Trans-Blot Turbo system (Bio-Rad). Membranes
were blocked by incubation for 1 h with 5% non-fat milk in PBS
containing 0.5% Tween-20 and blotted with specific antibodies to
TGFb-RII (C16) (1:1,000, sc-220, Santa Cruz Biotechnology), NOX4
(1:1,000, NB110-58851, Novus Biologicals, Littleton, CO), a-actin
(1A4) (1:2,000, sc-32251, Santa Cruz Biotechnology), fibronectin
(1:1,000, F7387) and phosphorylated Smad2 pSmad2 (Ser465/Ser467)
(1:1,000, 3101, Cell Signaling, Danvers, MA). After incubation with
IRDye 800 goat anti-rabbit and IRDye 600 goat anti-mouse (1:15,000,
LI-COR Biosciences, Lincoln, NE) secondary antibodies, membranes
were imaged in triplicates with the Odyssey Infrared Imaging System
(LI-COR Biosciences). Band sizing was performed using the ImageJ
1.42 software (http://rsb.info.nih.gov/ij) and relative protein expres-
sion was determined by normalizing to GAPDH (1:5,000, MAB374,
Millipore, Bedford, MA). Phospho-Smad2 activity was calculated by
normalizing to total Smad2 (D43B4) (1:1,000, 5339, Cell Signaling).
Protein fold changes were normalized to values of control cells.
Cell proliferation, cell viability and apoptosis assays
For cell counting, 20 × 103 lung fibroblasts per well were seeded into
24-well plates. HFL-1 cells were transfected with 40 nM pre-miRs.
Viable and non-viable cells were counted and the average cell
number from triplicate measurements was determined. After seeding
3 × 103 transfected cells per well in 96-well plates, cell viability was
determined with the XTT assay, using the Cell Proliferation Kit II
(Roche Diagnostics). Apoptotic cells were detected by FACS using
the PE Annexin V Apoptosis Detection Kit I (BD Biosciences
Pharmingen, San Diego, CA). Cells were analyzed in a BD FACSCan-
toTM II High Throughput Sampler flow cytometer (Becton Dickinson
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Bioscience). Apoptotic cell death was measured as PE Anexin
V-positive/7-AAD-negative cells.
Cell migration and invasion assays
Cellular migration and invasion assays were performed in 24-trans-
well permeable supports with 8.0 lm pore size (Corning, MA). In
brief, cells were transfected with 40 nM pre-miR-s as described
above. After 48 h, cells were detached with trypsin-EDTA (Gibco)
and 3 × 104 cells for migration and 5 × 104 cells per well for inva-
sion assays were suspended in serum-free F12K medium (ATCC)
and added to the upper chamber. Bottom wells were filled with
serum-free F12K medium containing 5 ng/ml TGF-b1 (R&D
Systems) as chemoattractant. For invasion assays inserts were pre-
coated with 50 ll of 300 lg/ml rat-tail collagen I (BD Biosciences)
at 37°C overnight. Cells were allowed to migrate or invade for 24
and 48 h at 37°C in 5% CO2. After incubation non-moving cells on
the top of the membrane were removed with a cotton swab.
Membranes containing cells were fixed with 4% paraformaldehyde
(PFA) for 10 min and washed with PBS. Nuclear staining was
performed with DAPI (Sigma-Aldrich) for 10 min. Membranes were
mounted on slides using mowiol (Calbiochem, Nottingham, U.K.).
Cell fluorescence was visualized in a Nikon Eclipse T2000U micro-
scope. To determine the total number of cells per insert, migratory
and invasive cells were counted in four random fields per slide
under light microscopy with a 10× objective lens. This count was
divided by the area of the viewing field and multiplied by the entire
area of the insert. The percentage of migrating/invading cells was
calculated by dividing this result by the total of cells seeded.
Immunofluorescence
HFL-1 cells were seeded onto 24-well plates containing 10-mm-
diameter glass coverslips. They were transfected with 40 nM
pre-miRs. After 24-h starvation cells were incubated with 5 ng/ml
TGF-b1 (R&D Systems) for the indicated times. After treatments
cells were fixed with 4% PFA for 10 min and permeabilized with
0.25% Triton X-100 in PBS for 5 min at room temperature. Cells
were washed with PBS, blocked with 1% BSA in PBS for 1 h and
incubated overnight at 4°C with anti-a-actin (1A4) (1:2,000,
sc-32251, Santa Cruz Biotechnology), anti-fibronectin (1:1,000,
F7387, Sigma-Aldrich) and anti-Smad2/3 (1:1,000, 610843, BD
Biosciences). Nuclear staining was performed with DAPI (Sigma-
Aldrich). F-actin was stained with tetramethylrhodamine isothiocyanate-
conjugated phalloidin (1:1,000, Sigma-Aldrich). The cover slips
were mounted on slides using mowiol (Calbiochem). Cell fluores-
cence was visualized by a Nikon Eclipse T2000U microscope.
Immunohistochemical analysis of mouse lung tissue
Lung tissue sections were deparaffinized and heated to expose the
hidden antigens using Real Target Retrieval Solution containing citrate
buffer, pH 6.0 (Dako, Glostrup, Denmark). Samples were pre-treated
with Real Peroxidase-Blocking Solution (Dako) to block endogenous
peroxidase. The primary antibodies employed were as follows: a-actin
(1A4) (1:600, sc-32251, Santa Cruz Biotechnology), TGFb-RII (C16)
(1:500, sc-220, Santa Cruz Biotechnology) and phospho-Smad2
(Ser465/Ser467) (1:600, 3101, Cell Signaling). Non-specific binding of
secondary antibodies was blocked by pre-treating slides with goat
serum. A biotinylated goat anti-rabbit IgG was applied to detect rabbit
primary antibodies and complexes were visualized using the R.T.U
Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, CA).
Mouse primary antibodies were visualized applying the Vector
M.O.M. Immunodetection Kit (Vector Laboratories, Burlingame, CA).
Tissue sections were revealed using DAB (Dako) as chromogen and
finally counterstained with hematoxylin. Slides were mounted with
mowiol (Calbiochem). Images were taken using a Leica DMD108
microscopy (Leica Microsystems CMS GmbH, Wetzlar, Germany).
miRNA in situ hybridization (ISH)
For detection of miR-9-5p in mouse lung samples a specific 50 and
30-DIG labeled miRCURY locked nucleic acidTM (LNA) oligonu-
cleotide (Exiqon, Denmark) was used (miR-9-5p detection probe
sequence: 50-TCATACAGCTAGATAACCAAAGA-30). The 50 and 30-
DIG labeled scramble miRNA (Exiqon) was used as a negative
control (scramble probe sequence: 50-GTGTAACACGTCTA
TACGCCCA-30). ISH was performed according to Exiqon’s protocol.
Sections were developed with nitro-blue tetrazolium chloride (NBT)/
5-bromo-4-chloro-3-indolyl-phosphate (BCIP) color substrates
(Roche Diagnostics). Slides were mounted with mowiol (Cal-
biochem). Positive blue cytoplasmic staining was observed with a
Nikon Eclipse T2000U microscope.
Lentiviral vector construct
The lentivector-based miRNA precursor constructs expressing the
miR-9-5p (lenti-miR-9) (MMIR-9-1-PA-1) and the scramble negative
control (lenti-SC) (MMIR-000-PA-1) were purchased from SBI
System Biosciences (Mountain View, California). Pseudoviral parti-
cles were prepared using the pPACK-F1 Lentivector packaging
system (SBI System Biosciences) and HEK 293T producer cell line.
The titration of pseudoviral particles generated with the lentiviral
vectors was determined by calculating the percentage of positive
GFP expression cells by flow cytometry in a BD FACSCantoTM II High
Throughput Sampler flow cytometer (Becton Dickinson Bioscience)
72 h after infection. The lentivirus titers were calculated as
described [80] and expressed in infection units (ifu)/ml.
Experimental pulmonary fibrosis model and in vivo delivery of
lentiviral vectors and miRNA inhibitors
C57BL/6 mice were purchased from Charles River Laboratory
(Wilmington, MA). LF was induced in 6–8-week-old C57BL/6 mice
by application of bleomycin (Sigma-Aldrich) as described [28] with
some modifications. Mice were anesthetized with intraperitoneal
injection of ketamine (100 mg/kg) plus xylazine (10 mg/kg). The
tongues of anesthetized mice were gently pulled forward with
forceps and bleomycin (1.5 U/kg body weight in 40 ll saline serum)
was delivered into the oropharyngeal cavity. To determine the effect
of miR-9-5p over-expression in the bleomycin-mice model of LF,
1 × 106 ifu/ml of lentivirus were diluted in 40 ll saline serum and
delivered into the mice oropharyngeal cavity 4 days before bleo-
mycin instillation. Delivery of lentiviral vectors was tested by detec-
tion of GFP expression in the lungs. To evaluate the persistence of
lentiviral transduction in our model miR-9-5p expression level was
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determined by qRT–PCR as described above. To modulate the
expression of miR-9-5p in vivo 7 mg/kg body weight in 40 ll saline
serum per mouse of miR-9-5p Inhibitor (miRNA Inhibitor miR-9-5p,
MH10022, mirVana custom Inhibitor, Ambion) was delivered into
the oropharyngeal cavity 4 and 2 days before bleomycin instillation.
Sequestering of miR-9-5p was determined by analysis of miR-9-5p
expression by qRT–PCR as described above. As controls WT
animals were provided with the same volume of saline serum,
lenti-SC, or miRNA Inhibitor Negative Control (miRNA Inhibitor
NC, 4464079, mirVana Inhibitor, Ambion). Mice were sacrificed at
the indicated time points and the PBS-perfused lungs were harvested
for analysis. The extent of LF was assessed by hematoxylin and
eosin (H&E) and Masson’s trichrome stainings in mice paraffin-
embedded lung samples. Images were taken using a Leica DMD108
microscopy (Leica Microsystems). mRNA expression levels were
determined by qRT–PCR. Total fibrotic areas per lung (mm2) were
quantified using the Digital Microimaging Device software (Leica
Microsystems). Histopathologic evaluation was performed in a
blinded fashion by two independent pathologists using a progressive
score (from grade 0 to 3). Fibrosis scoring included evaluation of
ECM deposits and presence of fibroblasts. Animals were handled in
agreement with the Guide for the Care and Use of Laboratory
Animals contained in Directive 2010/63/EU of the European Parlia-
ment. Approval was granted by the local ethics review board of
Centro de Biologı´a Molecular “Severo Ochoa” in Madrid.
Human IPF patients’ lung samples
Human lung tissue samples were obtained from surgical biopsies of
patients from Hospital “Ramon y Cajal” in Madrid, after written
approval and according to the Spanish and European legislation.
Seven lung tissue samples with the diagnosis of IPF and three
samples from histologically normal lungs (controls) from the Patho-
logy Department collection were selected. Samples were analyzed
by H&E and Masson’s trichrome stainings. Images were taken with
a DMD108 microscopy (Leica Microsystems). RNA extraction and
miR-9-5p expression level analysis were performed as described
above. The protocol was approved by the ethics committee of the
Hospital “Ramon y Cajal” in Madrid.
Statistical analysis
Data with only one grouping variable were analyzed with Kruskal–
Wallis non-parametric ANOVA with post-test multiple comparisons
using Dunn’s procedure or by nonparametric two-tailed Mann–
Whitney U-test. Differences between only two groups were analyzed
statistically with nonparametric two-tailed Mann–Whitney U-test.
Data were analyzed with use of version 5.01 of the GraphPad Prism
package (La Jolla, CA). A value of P < 0.05 was considered to be
statistically significant (*/#/@: P < 0.05, **/##: P < 0.01). Data are
reported as mean  SEM.
Expanded View for this article is available online:
http://embor.embopress.org
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